We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Issues Draft Bioequivalence Guidances for 30 Drugs, Revises 17
FDA Issues Draft Bioequivalence Guidances for 30 Drugs, Revises 17
The FDA published new product-specific draft guidances for 30 active ingredients — including cancer therapies, asthma treatments, epinephrine auto-injectors and anti-infectives — outlining the agency’s preferred methods for supporting ANDA submissions.